-
Something wrong with this record ?
Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies
O Krystufkova, Helmers S Barbasso, P Venalis, V Malmstrom, E Lindroos, J Vencovsky, IE Lundberg
Language English Country Great Britain
Grant support
NT12438
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
BioMedCentral
from 2003
BioMedCentral Open Access
from 2003
Directory of Open Access Journals
from 1999
Free Medical Journals
from 2003 to 6 months ago
PubMed Central
from 2003
Europe PubMed Central
from 2003
Open Access Digital Library
from 1999-01-01
Open Access Digital Library
from 1999-01-01
Open Access Digital Library
from 1999-10-01
Open Access Digital Library
from 2003-01-01
Medline Complete (EBSCOhost)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2003
Springer Nature OA/Free Journals
from 1999-06-01
- MeSH
- Antigens, CD19 metabolism MeSH
- Antibodies, Antinuclear immunology MeSH
- Autoantibodies * immunology MeSH
- B-Lymphocytes metabolism drug effects MeSH
- Biopsy MeSH
- Adult MeSH
- B-Cell Activating Factor biosynthesis MeSH
- Immunohistochemistry MeSH
- Interferon Type I pharmacology MeSH
- Microscopy, Confocal MeSH
- Middle Aged MeSH
- Humans MeSH
- B-Cell Maturation Antigen * biosynthesis MeSH
- Myositis * immunology metabolism pathology MeSH
- B-Cell Activation Factor Receptor * biosynthesis MeSH
- Transmembrane Activator and CAML Interactor Protein * biosynthesis MeSH
- Ribonucleoproteins immunology MeSH
- Aged MeSH
- Muscles * metabolism pathology MeSH
- Syndecan-1 metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
INTRODUCTION: Anti-Jo-1 and anti-Ro52 autoantibodies are common in patients with myositis, but the mechanisms behind their production are not known. Survival of autoantibody-producing cells is dependent on B-cell-activating factor of the tumour necrosis factor family (BAFF). BAFF levels are elevated in serum of anti-Jo-1-positive myositis patients and are influenced by type-I interferon (IFN). IFN-producing cells and BAFF mRNA expression are present in myositis muscle. We investigated expression of the receptors for BAFF in muscle tissue in relation to anti-Jo-1 and anti-Ro52/anti-Ro60 autoantibodies and type-I IFN markers. METHODS: Muscle biopsies from 23 patients with myositis selected based on autoantibody profile and 7 healthy controls were investigated for expression of BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Nineteen samples were assessed for plasma (CD138) and B-cell (CD19) markers. The numbers of positive cells per area were compared with the expression of plasmacytoid dendritic cell (pDC) marker blood dendritic cell antigen-2 (BDCA-2) and IFNalpha/beta-inducible myxovirus resistance-1 protein (MX-1). RESULTS: BAFF-R, BCMA and TACI were expressed in five, seven and seven patients, respectively, and more frequently in anti-Jo-1-positive and/or anti-Ro52/anti-Ro60-positive patients compared to controls and to patients without these autoantibodies (P = BAFF-R: 0.007, BCMA: 0.03 and TACI: 0.07). A local association of receptors with B and plasma cells was confirmed by confocal microscopy. The numbers of CD138-positive and BCMA-positive cells were correlated (r = 0.79; P = 0.001). Expression of BDCA-2 correlated with numbers of CD138-positive cells and marginally with BCMA-positive cells (r = 0.54 and 0.42, respectively; P = 0.04 and 0.06, respectively). There was a borderline correlation between the numbers of positively stained TACI cells and MX-1 areas (r = 0.38, P = 0.08). CONCLUSIONS: The expression pattern of receptors for BAFF on B and plasma cells in muscle suggests a local role for BAFF in autoantibody production in muscle tissues of patients with myositis who have anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. BAFF production could be influenced by type-I IFN produced by pDCs. Thus, B-cell-related molecular pathways may participate in the pathogenesis of myositis in this subset of patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17015472
- 003
- CZ-PrNML
- 005
- 20220411125115.0
- 007
- ta
- 008
- 170428s2014 xxkd f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13075-014-0454-8 $2 doi
- 035 __
- $a (PubMed)25301447
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kryštůfková, Olga, $d 1955- $7 xx0058260
- 245 10
- $a Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies / $c O Krystufkova, Helmers S Barbasso, P Venalis, V Malmstrom, E Lindroos, J Vencovsky, IE Lundberg
- 520 9_
- $a INTRODUCTION: Anti-Jo-1 and anti-Ro52 autoantibodies are common in patients with myositis, but the mechanisms behind their production are not known. Survival of autoantibody-producing cells is dependent on B-cell-activating factor of the tumour necrosis factor family (BAFF). BAFF levels are elevated in serum of anti-Jo-1-positive myositis patients and are influenced by type-I interferon (IFN). IFN-producing cells and BAFF mRNA expression are present in myositis muscle. We investigated expression of the receptors for BAFF in muscle tissue in relation to anti-Jo-1 and anti-Ro52/anti-Ro60 autoantibodies and type-I IFN markers. METHODS: Muscle biopsies from 23 patients with myositis selected based on autoantibody profile and 7 healthy controls were investigated for expression of BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Nineteen samples were assessed for plasma (CD138) and B-cell (CD19) markers. The numbers of positive cells per area were compared with the expression of plasmacytoid dendritic cell (pDC) marker blood dendritic cell antigen-2 (BDCA-2) and IFNalpha/beta-inducible myxovirus resistance-1 protein (MX-1). RESULTS: BAFF-R, BCMA and TACI were expressed in five, seven and seven patients, respectively, and more frequently in anti-Jo-1-positive and/or anti-Ro52/anti-Ro60-positive patients compared to controls and to patients without these autoantibodies (P = BAFF-R: 0.007, BCMA: 0.03 and TACI: 0.07). A local association of receptors with B and plasma cells was confirmed by confocal microscopy. The numbers of CD138-positive and BCMA-positive cells were correlated (r = 0.79; P = 0.001). Expression of BDCA-2 correlated with numbers of CD138-positive cells and marginally with BCMA-positive cells (r = 0.54 and 0.42, respectively; P = 0.04 and 0.06, respectively). There was a borderline correlation between the numbers of positively stained TACI cells and MX-1 areas (r = 0.38, P = 0.08). CONCLUSIONS: The expression pattern of receptors for BAFF on B and plasma cells in muscle suggests a local role for BAFF in autoantibody production in muscle tissues of patients with myositis who have anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. BAFF production could be influenced by type-I IFN produced by pDCs. Thus, B-cell-related molecular pathways may participate in the pathogenesis of myositis in this subset of patients.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a dospělí $7 D000328
- 650 02
- $a senioři $7 D000368
- 650 02
- $a antinukleární protilátky $x imunologie $7 D000974
- 650 02
- $a antigeny CD19 $x metabolismus $7 D018941
- 650 12
- $a autoprotilátky $x imunologie $7 D001323
- 650 02
- $a faktor aktivující B-buňky $x biosyntéza $7 D053264
- 650 12
- $a receptor faktoru aktivujícího B-buňky $x biosyntéza $7 D053265
- 650 12
- $a maturační antigen B-buněk $x biosyntéza $7 D053301
- 650 02
- $a B-lymfocyty $x metabolismus $x účinky léků $7 D001402
- 650 02
- $a biopsie $7 D001706
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a imunohistochemie $7 D007150
- 650 02
- $a interferon typ I $x farmakologie $7 D007370
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a konfokální mikroskopie $7 D018613
- 650 02
- $a lidé středního věku $7 D008875
- 650 12
- $a svaly $x metabolismus $x patologie $7 D009132
- 650 12
- $a myozitida $x imunologie $7 D009220
- 650 12
- $a myozitida $x metabolismus $x patologie $7 D009220
- 650 02
- $a ribonukleoproteiny $x imunologie $7 D012261
- 650 02
- $a syndekan-1 $x metabolismus $7 D053668
- 650 12
- $a receptor TACI $x biosyntéza $7 D053303
- 700 1_
- $a Barbasso Helmers S
- 700 1_
- $a Venalis P
- 700 1_
- $a Malmstrom V
- 700 1_
- $a Lindroos E
- 700 1_
- $a Vencovský, Jiří, $d 1953- $7 jo20000080529
- 700 1_
- $a Lundberg IE
- 773 0_
- $t Arthritis Research & Therapy $g Roč. 16, č. 5 (2014), s. 454 $p Arthritis Res Ther $x 1478-6354 $w MED00007534
- 773 0_
- $p Arthritis Res Ther $g 16(5):454, 2014 Oct 10
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20170428105123 $b ABA008
- 991 __
- $a 20220411125113 $b ABA008
- 999 __
- $a ok $b bmc $g 1202720 $s 976259
- BAS __
- $a 3
- BMC __
- $a 2014 $b 16 $c 5 $d 454 $x MED00007534 $i 1478-6354 $m Arthritis research & therapy
- GRA __
- $a NT12438 $p MZ0
- LZP __
- $a NLK 2015-B/lp